PCNII COST-EFFECTIVENESS OF ORAL IBANDRONATE VERSUS IV ZOLEDRONIC ACID OR IV PAMIDRONATE IN THE TREATMENT OF BREAST CANCERWITH BONE METASTASES IN PATIENTS UNDERGOING IV CHEMOTHERAPY IN THE UK
Abstract
Authors
E De Cock J Hutton P Barrett-Lee P Canney JJ Body M Neary GJ Lewis